News
Number 5: New research shows that denosumab biosimilar SB16 is equivalent to the reference product, Prolia (denosumab), up to ...
A 10-year prospective follow-up of 244 healthy stem cell donors found no new safety concerns with Sandoz’s filgrastim ...
Explore groundbreaking developments in biosimilars, including patent lawsuits, new ustekinumab launches, and innovative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results